In a new study from the University of Münster, researchers found a new a drug candidate against SARS-CoV-2 infections.
This could constitute the basis for a broadly effective drug to fight COVID-19.
The findings provided the basis for the approval issued by the German Institute of Drugs and Medicinal Products for a clinical study currently being worked on.
In the study, the team found the drug can not only inhibit the proliferation of SARS-CoV-2 viruses in cells, but also reduce the exaggerated immune response which represents a serious problem in severe cases of COVID.
They say that they have been able for the first time to show such a dual action for an anti-COVID-19 agent.
The active agent in question, called Zapnometinib or ATR-002, was originally under development as an anti-flu medication.
It was effective in a variety of cell culture models—including activity against all tested variants of SARS-CoV-2, which also implies broad applicability in facing up to any coming variants in the future.
The team says positive results from the still ongoing clinical study in humans might already lead to an emergency approval this year for a new, broadly effective COVID-19 medication. The benefit is clear.
If you care about COVID, please read studies that CBD from cannabis may inhibit COVID-19 infection, and this low-cost drug can treat COVID-19 effectively and safely.
For more information about health, please see recent studies about super-antioxidant that could revolutionize your health, and results showing scientists find antibodies that can neutralize Omicron.
The study is published in the journal Cellular and Molecular Life Sciences and was conducted by Prof. Stephan Ludwig et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.
